Ordeniza, Lexie Zane Y.
HRN: 21-35-76 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/18/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/18/2022
10/25/2022
IVTT
100mg
Q24h
Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Unspecified Sepsis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes